Swedish Orphan Biovitrum AB (LTS:0MTD) Net Margin % : 12.79% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Swedish Orphan Biovitrum AB's Net Income for the three months ended in Mar. 2024 was kr800 Mil. Swedish Orphan Biovitrum AB's Revenue for the three months ended in Mar. 2024 was kr6,256 Mil. Therefore, Swedish Orphan Biovitrum AB's net margin for the quarter that ended in Mar. 2024 was 12.79%.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Net Margin % or its related term are showing as below:

LTS:0MTD' s Net Margin % Range Over the Past 10 Years
Min: -10.27 Med: 16.33 Max: 26.46
Current: 9.26

LTS:0MTD's Net Margin % is ranked better than
70.52% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 3.76 vs LTS:0MTD: 9.26

Swedish Orphan Biovitrum AB Net Margin % Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Net Margin % Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

23.19

21.26

17.25

14.04

10.89

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial															20.37	4.56	1.82	14.99	12.79

Competitive Comparison of Swedish Orphan Biovitrum AB's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Net Margin % falls into.

Swedish Orphan Biovitrum AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Swedish Orphan Biovitrum AB's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	2409	/	22123
	=	10.89 %

Swedish Orphan Biovitrum AB's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	800	/	6256
	=	12.79 %

Swedish Orphan Biovitrum AB (LTS:0MTD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Swedish Orphan Biovitrum AB Net Margin % Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK B6E:Germany B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines